Halozyme appoints Mark Snyder as General Counsel; Matsuda steps down Dec 31

HALOZYME THERAPEUTICS, INC.

Masaru Matsuda steps down as SVP, General Counsel, Chief Compliance Officer and Corporate Secretary effective Dec 31, 2021 to pursue another opportunity.
Mark Snyder appointed to those roles effective Jan 3, 2022; previously SVP, Deputy General Counsel, Litigation at Qualcomm.
Snyder brings nearly 30 years of legal experience, including IP, licensing, regulatory, antitrust, and litigation.
Company expects to enter a separation agreement with Matsuda with benefits consistent with those disclosed in 2018 8-K.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Snyder

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2022-01-03
Filed: December 13, 2021, 6:59 PM ET

Effective January 3, 2022, Mark Snyder will be appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company.

Departed

Masaru Matsuda

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2021-12-31
Successor: Mark Snyder
Filed: December 13, 2021, 6:59 PM ET

Masaru Matsuda will step down from his position as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company, effective December 31, 2021, to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Snyder was appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at HALOZYME THERAPEUTICS, INC..

Action: will be appointed
Role: Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Exact text from the filing

Effective January 3, 2022, Mark Snyder will be appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Masaru Matsuda departed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at HALOZYME THERAPEUTICS, INC..

Action: will step down
Role: Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Exact text from the filing

Masaru Matsuda will step down from his position as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company, effective December 31, 2021, to pursue another opportunity.

View on SEC.gov

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-21-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.